Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 4,540,000 shares, a decline of 17.5% from the December 15th total of 5,500,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 3.5 days.

Analyst Ratings Changes

A number of research firms have recently weighed in on ZNTL. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Guggenheim cut their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.00.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Decheng Capital LLC increased its stake in Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company's stock valued at $12,558,000 after acquiring an additional 970,859 shares during the period. Verition Fund Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Primecap Management Co. CA raised its holdings in shares of Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock worth $5,513,000 after buying an additional 265,690 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock valued at $2,706,000 after buying an additional 399,745 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock valued at $2,240,000 after acquiring an additional 353,384 shares during the period.

Zentalis Pharmaceuticals Stock Down 16.1 %

Shares of ZNTL stock traded down $0.46 during trading hours on Thursday, reaching $2.39. 3,439,621 shares of the company's stock were exchanged, compared to its average volume of 1,788,982. The stock has a market capitalization of $170.31 million, a P/E ratio of -0.96 and a beta of 1.86. Zentalis Pharmaceuticals has a fifty-two week low of $2.34 and a fifty-two week high of $18.07. The business has a fifty day moving average price of $3.27 and a 200-day moving average price of $3.41.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, research analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.